Showing 3981-3990 of 8682 results for "".
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat
- Lebrikizumab Shows Sustained AD Control Up to 3 Years in More 80%https://practicaldermatology.com/news/lebrikizumab-shows-sustained-ad-control-3-years-more-80/2468297/More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to 3 years experienced sustained skin clearance with monthly maintenance dosing, Almirall
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- INTEGUMENT Trials: Once-Daily Roflumilast Cream Reduces AD Symptomshttps://practicaldermatology.com/news/integument-trials-once-daily-roflumilast-cream-reduces-ad-symptoms/2468245/Roflumilast cream, 0.15%, significantly improved symptoms of mild to moderate atopic dermatitis (AD) in two phase 3 clinical trials. Researchers for the INTEGUMENT-1 and INTEGUMENT-2, publishing their results in JAMA Dermatology, evaluated the efficacy and safety of roflumilast cr
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released
- Cord Blood Biomarkers and TEWL Predict Atopic Dermatitis in Infantshttps://practicaldermatology.com/news/cord-blood-biomarkers-and-tewl-predict-atopic-dermatitis-infants/2468171/A prospective study reports that elevated levels of CCL17 and IL-31 in cord blood, along with increased transepidermal water loss (TEWL) at the anterior cubital fossa, could help identify infants at higher risk of developing atopic dermatitis (AD) within their first year of life. The study
- Study Identifies Key Patient-Centered Attributes of Atopic Dermatitis Flarehttps://practicaldermatology.com/news/study-identifies-key-patient-centered-attributes-ad-flare/2468156/A new study revealed a consensus on the patient-centered definition of an atopic dermatitis (AD) flare. Researchers for the study recruited 26 participants for focus groups and 631 participants for a survey through the National Eczema Association. The participants rated various attributes
- Age-related Fibroblast Changes Drive Melanoma in Males, Study Sayshttps://practicaldermatology.com/news/age-related-fibroblast-changes-drive-melanoma-males-study-says/2468115/Age-related changes in fibroblasts contribute to development of aggressive, treatment-resistant melanoma in males, according to a Johns Hopkins Kimmel Cancer Center study published in Cell. The authors of the study, Dr. Ashani Weeraratna and colleagues, had previously shown in studies that
- CHE Studies Presented at ESCD 2024 Congresshttps://practicaldermatology.com/news/che-studies-presented-escd-2024-congress/2468089/LEO Pharma A/S presented a range of new population-level and physician-reported data on the prevalence, severity, and treatment of moderate-to-severe chronic hand eczema (CHE). The data forms part of an expansive scientific program from LEO Pharma. Eight posters in total will be shared at the Eur